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Aim To assess practical accuracy of revised Bethesda cri-
teria (BGrev), pathological predictive model (MsPath), and 
histopathological parameters for detection of high-fre-
quency of microsatellite instability (MSI-H) phenotype in 
patients with colorectal carcinoma (CRC).
Method Tumors from 150 patients with CRC were ana-
lyzed for MSI using a fluorescence-based pentaplex poly-
merase chain reaction technique. For all patients, we eval-
uated age, sex, family history of cancer, localization, tumor 
differentiation, mucin production, lymphocytic infiltration 
(TIL), and Union for International Cancer Control stage. 
Patients were classified according to the BGrev, and the 
groups were compared. The utility of the BGrev, MsPath, 
and clinical and histopathological parameters for predict-
ing microsatellite tumor status were assessed by univariate 
logistic regression analysis and by calculating the sensitiv-
ity, specificity, and positive (PPV) and negative (NPV) pre-
dictive values.
Results Fifteen out of 45 patients who met and 4 of 105 
patients who did not meet the BGrev criteria had MSI-H 
CRC. Sensitivity, specificity, PPV, and NPV for BGrev were 
78.9%, 77%, 30%, and 70%, respectively. MSI histology (the 
third BGrev criterion without age limit) was as sensitive as 
BGrev, but more specific. MsPath model was more sensitive 
than BGrev (86%), with similar specificity. Any BGrev crite-
rion fulfillment, mucinous differentiation, and right-sided 
CRC were singled out as independent factors to identify 
MSI-H colorectal cancer.
Conclusion The BGrev, MsPath model, and MSI histology 
are useful tools for selecting patients for MSI testing.
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Microsatellite instability (MSI) is a hallmark of mismatch re-
pair (MMR) deficiency in hereditary nonpolyposis colorectal 
cancer (HNPCC). Because these carcinomas were observed 
to develop in the absence of polyposis, the term HNPCC 
was used instead of Lynch syndrome (LS). Moreover, HN-
PPC corresponds to at least two different entities, LS and 
type X familial colorectal cancer (1). LS is always character-
ized by germline defect of mismatch repair system and is 
associated with an increased lifetime risk for cancer, pre-
dominantly colorectal and endometrial cancer.
Testing for MSI is an important tool for identification of 
patients with hereditary colorectal cancer, because ap-
proximately 90% of HNPCC-associated colorectal tumors 
are characterized by MSI (2). Clinical criteria facilitated the 
identification of the molecular basis of HNPCC (3). Because 
the original criteria (Amsterdam criteria) were considered 
to be too restrictive (4,5), extended criteria were estab-
lished (Amsterdam II criteria), which took into account oth-
er types of HNPCC-associated cancer, such as cancer of the 
endometria, small bowel, ureter, and renal pelvis (6-8). The 
use of the Amsterdam criteria achieved the original pur-
pose of classifying HNPCC families but their limited sensi-
tivity hampered decisions about which patients should un-
dergo genetic testing. In 1996, an international workshop 
on HNPCC hosted by the National Cancer Institute out-
lined a set of recommendations, known as the Bethesda 
guidelines, for the identification of individuals with HNPCC 
who should be tested for MSI and/or genetic testing (4). 
The Bethesda guidelines initially proved to be highly sensi-
tive, but were considered too indefinite and unsuitable for 
primary sequence analysis of MMR genes (4). The second 
HNPCC workshop revised these criteria and proposed a 
new set of recommendations, the revised Bethesda guide-
lines. The revised Bethesda guidelines (BGrev; Table 1) were 
published in 2004 (3). The purposes of revising the BGrev 
were better identification of patients at risk for hereditary 
colorectal cancer and identification if CRC is likely to be 
MSI-H. Four of the 5 criteria that make up these guidelines 
are based on family and personal history of Lynch-related 
tumors, whereas the fifth criterion is based on tumor his-
tology (Table 1) (3).
In 2007, Jenkins et al (9) published the MsPath model 
that used easily assessable clinicopathologic characteris-
tics to capture all colorectal cancers with high frequency 
of microsatellite instability (MSI-H) presenting in patients 
younger than 60 years, the age group most likely to be as-
sociated with LS, while ruling out colorectal cancers that 
are highly unlikely to be MSI-H. This model (9) considers 
six clinicopathological features (with the corresponding 
coefficient): age at diagnosis (<50-year -0.7), anatomical 
site (cecum, ascending or transverse colon -1.6), histolog-
ic type (mucinous, signet ring, or undifferentiated -1.1), 
grade (poorly differentiated -0.6), Crohn-like reaction 
(present -0.5), and tumor-infiltrating lymphocytes (TILs) 
(present -2.1). Authors (9) have recommended a cut-
off MsPath score of 1.0 to maximize the specificity while 
maintaining a high sensitivity, because it is important not 
to miss MSI-H cases.
MSI-H histology has been incorporated into the BGrev 
(third criterion BGrev, without age limit) for identifying pa-
tients with colorectal cancer for further genetic analysis.
The aim of the study was to evaluate clinical and patho-
logical parameters in a regional cohort of Serbian unse-
lected colorectal cancer patients who were tested for MSI 
in tumor tissue. We analyzed practical validity of revised 
Bethesda criteria, MSI histology, and MsPath model (9) for 
detection of MSI-H phenotype in CRC, by determination 
of sensitivity, specificity, positive (PPV), and negative (NPV) 
predictive value.
MethoDS
One hundred and fifty primary colorectal carcinomas 
were randomly selected for MSI testing and excised 
surgically at the Clinic for Digestive Surgery, Clinical 
tABle 1.  Revised Bethesda Guidelines (BGrev); just one of 
these criteria needed to be met (3)
B1 Individuals diagnosed with colorectal cancer before the age 
of 50 y
B2 Synchronous or metachronous colorectal or other HNPCC*-
related tumors (which include stomach, bladder, ureter, renal 
pelvis, biliary tract, brain (glioblastoma), sebaceous gland ad-
enomas, keratoacanthomas and carcinoma of the small bowel), 
regardless of age
B3 Colorectal cancer with a high-microsatellite instability mor-
phology† that was diagnosed before the age of 60 y
B4 Colorectal cancer with one or more first-degree relatives with 
colorectal cancer or other HNPCC-related tumors. One of the 
cancers must have been diagnosed before the age of 50 y (this 
includes adenoma, which must have been diagnosed before the 
age of 40 y)
B5 Colorectal cancer with two or more relatives with colorectal 
cancer or other HNPCC-related tumors, regardless of age
*hNPCC – hereditary nonpolyposis colorectal cancer.
†Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic 
reaction, mucinous/signet ring differentiation, or medullary growth 
pattern.
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Centre of Serbia, Belgrade, from January 2007-September 
2010. The study was approved by the ethics committee of 
the Clinical Centre. Patients treated by preoperative radio-
therapy or chemotherapy, those with inflammatory bowel 
disease, or a known history of familial adenomatous poly-
posis were excluded. Family history data were obtained 
through an interview with each patient at hospital admis-
sion. Patients who fulfilled the Amsterdam criteria were 
also excluded. Fresh representative tissue samples from all 
150 tumors were immediately frozen at -80°C and tested 
for MSI. The genomic DNA was extracted using QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol (10).
Five mononucleotide markers, BAT-25, BAT-26, NR-21, NR-
22, and NR-24, were coamplified in a single pentaplex 
polymerase chain reaction (PCR) mix containing QIAGEN 
Multiplex PCR Kit, five fluorescent primers set in a final con-
centration of 0.25 μmol/L for each primer, and 100 ng of 
DNA, in the previously described conditions (11). The size of 
PCR products and the corresponding fluorescent label Gene 
Scan 500LIZ Size Standard were analyzed in ABI PRISM 3130 
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) 
using Gene Mapper Software, version 3.7. The size of PCR 
products and the corresponding fluorescent labels were 
chosen so as to allow simultaneous analysis of normal-sized 
alleles, with the smaller-sized alleles containing deletions 
typically seen in MSI-H tumors. Tumors were classified as 
MSI-H if three or more out of five markers showed MSI and 
as microsatellite stable/with low frequency of microsatellite 
instability (MSS/MSI-L) if none or fewer than three markerss-
howed MSI. Patients were divided into two groups based on 
revised Bethesda criteria (BGrev + patients who fulfilled any 
of the criteria and BGrev- patients who did not fulfill any of 
the criteria). The following pathological parameters were ex-
amined independently by an experienced pathologist: mu-
cin production graded as present or none, tumor-infiltrat-
ing lymphocytes (TILs) graded also as present (at least 5 per 
high power field) or none, and tumor differentiation graded 
as poor, moderate, and good. Sensitivity, specificity, PPV, NPV 
of BGrev, MSI histology, MsPath model, and pathological pa-
rameters (presence of any mucin, TILs, poor differentiation) 
for detecting MSI-H CRC were calculated.
Statistical analysis
Results are expressed as mean ± standard deviation for 
parametric data and counts for non-parametric data. Sta-
tistical analysis was performed between groups using in-
dependent samples t-test to analyze numerical parame-
ters (of normally distributed variables), while asymptotic χ2 
and χ2 likelihood ratio tests were used for non-parametric 
data. Univariate logistic regression analysis was performed 
to identify significant predictors of MSI status and to calcu-
late the odds ratio (OR). The utility of different parameters 
at predicting MSI status was compared by assessing the 
sensitivity, specificity, positive (PPV) and negative (NPV) 
predictive values, which were calculated using standard 
definition (12). Statistical analysis was performed with SPSS 
15.0 software (SPSS Inc., Chicago, IL, USA). All P values low-
er than 0.05 were considered as significant.
ReSultS
A total of 150 patients were enrolled (60 women, 90 men; 
mean age at diagnosis, 61 ± 10.3 years). Forty seven pa-
tients had left-sided colorectal cancer (in the descending 
and sigmoid colon), 28 had right-sided colorectal cancer 
(in the transverse colon, ascending colon, or cecum), and 
75 had rectal cancer. The cohort included synchronous or 
metachronous colorectal cancer in 5 patients.
tABle 2. Number of patients who met the revised Bethesda criteria and microsatellite instability status of these patients
B1(<50 y) B2 B3 B4 B5 B1+B3 B3+B4 B1+B3+B5 Σ
Number of patients 16 5 11 4 2 4 2 1 45
High frequency of microsatellite instability  0 1  4 4 2 1 2 1 15
Microsatellite stable /low frequency of microsatellite instability 16 4  7 0 0 3 0 0 30
FIGuRe 1. Performance of microsatellite markers to detect microsatellite 
instability (MSI, N = 19). the microsatellite markers showed MSI in the fol-
lowing percentages of high-level MSI (MSI-h) cases: BAt25, 100%; BAt26, 
100%; NR21, 94%; NR22, 79%; and NR24 89%.
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Forty five of the 150 patients with colorectal cancer (30%) 
fulfilled at least one of the five revised Bethesda criteria (Ta-
ble 1), whereas 105 patients (70%) fulfilled none. The most 
commonly fulfilled criteria were B1 and B3 (Table 2). The 
distribution of sex, Union for International Cancer Control 
(UICC) tumor stage, and pathological grading were simi-
lar in the patients who did and did not fulfill the revised 
Bethesda criteria (Table 3).
Microsatellite instability was detected in 19 of the 150 pa-
tients with colorectal cancer (12.6%). The results obtained 
with the individual microsatellite markers are summarized 
in Figure 1. The mononucleotide repeat markers BAT26 
and BAT25 were most sensitive. Fifteen of the 45 patients 
who met the revised Bethesda criteria (30%) and 4 of the 
105 patients who met none of the revised Bethesda cri-
teria (3.4%) had a tumor with microsatellite instability. In 
the group of patients with synchronous or metachronous 
colorectal cancer, one patient had MSI-H, one had MSI-L 
(BAT25), and 3 had MSS CRC. Characteristics of patients 
with CRC and MSI are shown in Tables 3,4,5.
The sensitivity of the revised Bethesda criteria to detect mi-
crosatellite instability in our cohort was 79% (confidence 
interval [CI], 54% to 93%), and the specificity was 77% (CI, 
68.7% to 83.7%). Positive and negative predictive value was 
30% and 70%, respectively. When the age limit of 45 years 
was used in the first criterion of BGrev (instead 50 years), the 
specificity was 89%, while sensitivity, PPV, and NPV did not 
significantly change. We estimated the utility of the B3 cri-
terion, MSI histology (B3 criterion without age limit, defined 
by presence of TILs, Crohn’s-like lymphocytic reaction, mu-
cinous/signet ring differentiation, or medullar growth pat-
tern), TILs, mucinous and poor tumor differentiation, family 
history of cancers (B4, B5 criteria together) for identification 
MSI-H tumors. Specificity, sensitivity, PPV, and NPV for these 
parameters are given in the Table 6. MsPath model with rec-
ommended cut-off score of 1.0 identified 84% of our MSI-H 
tumors (patients below the age of 60 years). The sensitivity 
and specificity were 86% and 85%, respectively.
tABle 3. Patients’ clinical characteristics, according to fulfill-
ment (BGRev+) or nonfulfillment (BGRev-) of at least one 










Women/men 43/62 17/28 60/90  0.351*
Mean age ± standard 
deviation (range)
65.1 ± 10.3 51.6 ± 9.9 61.08 ± 10.3 <0.001†
localization:
rectum 52 23 75  0.712*
left colon 34 13 47
right colon 19  9 28
Patients with synchro-
nous or metachronous 
colorectal cancer
 0  5  5
union for International 
Cancer Control disease 
stage:
I  7  6 13  0.572*
II 38 14 52
III 46 19 65
IV 14  6 20
*χ2 test.
†t-test.
tABle 4. Patients’ histopathological characteristics and microsatellite instability (MSI) status, according to fulfillment (BGRev+) or 












1 (present)  38 18  56 0.130*
2 (absent)  67 27  94
Differentiation:
1 (undifferentiated and poorly differentiated)  11  4  15 0.632*
2 (moderately differentiated)  45 20  65
3 (well differentiated)  49 21  70
Mucin production:
present  77 21  98 0.023* 3.1 (4.1-4.4)†
absent  28 24  52
MSI status:
High frequency of microsatellite instability   4 15  19 0.0001* 7 (2.5-19.9)†
Microsatellite stable/low frequency of microsatellite instability 101 30 131
*χ2 test.
†Mantel-haenszel test.
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Eight clinicopathological features were included into univar-
iate logistic regression analysis – diagnostic age lower than 
60 years, male sex, right-sided colon cancer, poor differen-
tiation, mucinous differentiation, the presence of TILs, lower 
disease stage (I and II UICC stage), and any BGrev criterion 
fulfillment. Any BGrev criterion fulfillment, mucinous differ-
entiation, and right-sided CRC were singled out as indepen-
dent factors to identify MSI-H colorectal cancer (Table 7).
Pathological parameters (tumor differentiation, mucin pro-
duction, and TILs) were compared between BGrev + and 
BGrev- patients. There were no significant differences be-
tween the groups, when differentiation and TILs were used 
as grouping criteria. Mucinous carcinomas were signifi-
cantly more frequently present in BGrev + group (odds ra-
tio 3.14; 95% CI, 1-4.4; P = 0.02) (Table 4).
DISCuSSIoN
In this prospective study of unselected and consecutively 
diagnosed CRC patients, we assessed the performance of 
currently used clinical guidelines (BGrev) against a molecu-





















 1 m 44 1 rectum T2N0M0,GI no B1, B3 yes
 2 f 64 1 ascending colon T2N0M0,GIII yes B4 yes
 3 m 68 1 rectum T3N1M0,GII yes B4 yes
 4 m 72 2 cecum and rectum T2N0M0,GII
T3N0M0,GIII
no B2 no
 5 m 52 1 cecum T4bN2M0,GII yes B3 yes
 6 m 56 1 rectum T3N0M0, GII yes B3,B4 yes
 7 m 64 1 cecum T2N0M0,GI yes B4 yes
 8 f 63 1 cecum T2N1M0, GII yes B5 yes
 9 m 41 1 rectum T1N0M0GIII yes B1,B3,B5 no
10 m 58 1 ascending colon T3N0M0, GII no B3 no
11 m 66 1 descending colon T1N0M0, GII yes B5 no
12 m 57 1 rectum T3N1M0, GII no B3 yes
13 m 57 1 ascending colon T3N1M0, GIII no B3 yes
14 m 59 1 sigmoid colon T4aN0M0, GII no B3 yes
15 m 59 1 descending colon T2N0M0,GI yes B4,B3 yes
16 f 70 1 transverse colon T3N0M0, GII no - no
17 f 76 1 ascending colon T4bN1M1,GII no - no
18 m 71 1 rectum T3N1M0, GI no - no
19 m 68 1 ascending colon T3N0M0,GII no - no
*hNPCC – hereditary nonpolyposis colorectal cancer.







B3 criterion 0.44 0.91 0.13 0.87
MSI histology 0.79 0.85 0.20 0.80
MsPath score* 0.86 0.85 0.18 0.82
Tumor infiltrating lymphocytes 0.52 0.65 0.37 0.63
Any mucinous differentiation 0.63 0.69 0.34 0.65
Poor differentiation 0.27 0.89 0.13 0.88
Family history of cancers (B4.B5) 0.64 0.92 0.13 0.87
Revised Bethesda guidelines 0.78 0.77 0.3 0.7
Revised Bethesda guidelines (modified B1, age limit <45 y) 0.78 0.89 0.19 0.80
*Cut-off value = 1.
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lar tumor marker (MSI). The frequency of high microsatellite 
instability phenotype in our cohort was 12.6%. Nearly 80% 
of MSI-H CRCs were identified using BGrev, and the specific-
ity of MsPath model and MSI histology was higher than that 
of BGrev. Among other clinical and pathological features, 
mucinous differentiation and right-sided CRC were inde-
pendent factors for identifying MSI-H colorectal cancer.
In the early 1990s, the genetic defect responsible for LS was 
identified as a germline mutation in one of the DNA MMR 
genes with the consequence of a microsatellite instability 
phenotype (13). Introducing the MSI determination as an 
initial screening test for CRC enables the molecular detec-
tion of LS in large populations. MSI-H has been shown to 
have a dominant impact on the global molecular pheno-
type in CRC. MSI-H CRC shows distinct clinicopathological 
features, including both better prognosis (14,15) and re-
duced response to 5-fluorouracil/leucovorin (5-FU) adjuvant 
chemotherapy (16,17). Moreover, patients with MSS tumors 
(especially stage III cancers) seem to benefit most from ad-
juvant 5FU chemotherapy. Conversely, patients with MSI tu-
mors and more specifically those with stage II cancer, do not 
seem to benefit from adjuvant chemotherapy (16,17). Both 
the MSI test and immunostaining have been shown to be 
highly effective for selecting patients who should be tested 
for hMSH2/hMLH1 germline mutations (18). In this study, we 
did not include patients who fulfilled the Amsterdam criteria 
for HNPCC, because in our and other opinions (2,6), patients 
with CRCs belonging to HNPCC families should be proceed-
ed immediately to MMR gene mutation analysis. These pa-
tients do not need the MSI analysis.
In a recent study (19), the usefulness of BGrev for MSI predic-
tion was assessed with and without B3. In this cohort, 2/3 
patients with MSI-H were identified by the BGrev, resulting 
in a sensitivity and specificity of 66.7% and 50.9%, respec-
tively. The sensitivity of MSI histology in the same study (19) 
was 82.5%, while the specificity was lower, 27.1%. In our co-
hort, MSI histology had lower sensitivity (78.9%) and high-
er specificity (84.7%) than BGrev. In 2007, Jenkins et al (9) 
published the MsPath model for predicting MSI in CRC. This 
model did not include family history, but included histol-
ogy features described in the B3 criterion (Table 1) with tu-
mor localization and age at diagnosis. MsPath model is only 
applied to patients diagnosed before the age of 60 years. 
MsPath score ≥1.0 had a sensitivity of 93% and a specificity 
of 55% for MSI-H tumors (9). Applied MsPath model with 
recommended cut-off score of 1.0 in our cases had an in-
creased sensitivity of 86%. The specificity of MsPath mod-
el and BGrev in our cohort was similar. Differences, espe-
cially in specificity, between our and other studies can be 
explained by the fact that our cohort was unselected. A 
large number of patients with MSI-H CRCs are older than 60 
years and they would be missed by this model. In our study, 
more than half patients with MSI-H tumor were older than 
60 years. It is likely that these cases are sporadic MSI-H CRCs. 
In sporadic MSI-H CRC, MSI occurs due to MLH1 genes pro-
moter methylation. Five patients with MSI-H CRC were be-
tween 50 and 60 years and they all met B3. The possibility of 
LS diagnosis in these cases is higher. Moreover, the analysis 
of the MMR defect discriminating sporadic from hereditary 
MSI-H cases needs to be developed in order to be able to 
recognize Lynch cases in Serbia.
An important finding was that the specificity of revised 
Bethesda criteria could be increased using the lower age 
limit in the B1 criterion (<45 years instead <50 years) as 
used in the previous Bethesda criteria. Twenty one patients 
in our cohort were younger than 50 years. Among these 
patients, only two (10%) had MSI-H tumors and both were 
younger than 45 years. When the age limit in the B1 crite-
rion was 45 years, BGrev were more specific. However, this 
observation is only hypothetical and is not applicable in 
practice as long as germline mutation is not determined 
to confirm the final diagnosis of LS.
Regarding the patients presenting with synchronous or 
metachronous colonic tumors, four patients were MSS and 
only one was MSI-H, and this is another reason for the low 
PPV and higher specificity of the BGrev in our study popu-
lation (great number of false positives).
Another study (20) concluded that tumor localization, 
rather than MSI histology, might have a key role in 
tABle 7. univariate logistic regression analysis of clinical and 






Male sex 2.59 0.8-8.2 0.125
Age less than 60 y 1.74 0.4-3.6 0.344
Right-sided CRC 8.5 2.7-26.7 0.001
Poor and well differentiation 2.18 0.8-7.3 0.181
Any mucinous differentiation 3.272 1.2-8.7 0.040
TIL>5/HPF 2.21 0.8-5.4 0.158
Lower disease stage 
(UICC stage; I and II)
1.06 0.3-2 0.918
Any BGrev criterion fulfillment 6.99 2.5-19.9 0.001
*Abbreviations: CRC – colorectal cancer; tIl – tumor infiltrating lym-
phocytes; hPF – high-powered field; uICC – union for International 
Cancer Control staging; BGrev – Revised Bethesda guidelines.
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detecting CRC with MSI-H phenotype. These authors sug-
gested that in a future revision of criteria for MSI testing, 
tumor localization should play as great a role as age at the 
onset of the CRCs, and the Bethesda criteria should be 
broadened to include patients 51-60 years old with proxi-
mal colon cancer. Our findings support this claim.
We found that identification of mucinous histology, even 
if seen only focally, was significant, independent predictor 
of MSI-H CRC. Others (19,21) have reported similar find-
ings. In one study (22), the specificity of TILs for MSI-H CRC 
reached 98.2%, while the sensitivity was low (33.3%). Our 
results showed lower TILs specificity and higher sensitiv-
ity. In our study, TILs was not an independent predictive 
factor for MSI-H CRC. Results from other studies (19,23,24) 
were different. Tumor differentiation was another feature 
that was not an independent predictor of MSI-H in our 
study but was in others (25-27). Greenson et al (21) consid-
ered well and poor differentiated tumors together, which 
indicated an increased likelihood of MSI. We assessed the 
grade using both of these models, and no significance was 
found. Poor differentiation proved to be a specific param-
eter for MSI-H CRC. Proximal tumors were more likely to 
show MSI-H phenotype than distal tumors, which concurs 
with the results from other studies (28,29).
The main limitation of our study was the inability to analyze 
germline mutations of MMR genes for MSI-H tumors. Anoth-
er limitation was the fact that only routine histopathologi-
cal parameters that were included in the BGrev and MsPath 
model (9) were analyzed, so we were not able to examine 
the validity of newer proposed models for the prediction of 
MSI-H (19,21). Also, the selection of patients based on their 
age was not made, so the validity of clinical and histopatho-
logical parameters can be reliably observed.
In conclusion, BGrev are useful to select patients at risk for 
hereditary cancer, by increasing the detection rate of mic-
rosatellite instability as MSI histology. MsPath model proved 
to be more sensitive than BGrev, with similar specificity. 
Moreover, BGrev, MsPath model, and MSI histology are use-
ful tools for selecting patients with CRC for MSI testing.
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